KR20230004508A - 코로나바이러스 백신 및 사용 방법 - Google Patents

코로나바이러스 백신 및 사용 방법 Download PDF

Info

Publication number
KR20230004508A
KR20230004508A KR1020227036217A KR20227036217A KR20230004508A KR 20230004508 A KR20230004508 A KR 20230004508A KR 1020227036217 A KR1020227036217 A KR 1020227036217A KR 20227036217 A KR20227036217 A KR 20227036217A KR 20230004508 A KR20230004508 A KR 20230004508A
Authority
KR
South Korea
Prior art keywords
sequence
epitope
composition
pharmaceutical composition
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227036217A
Other languages
English (en)
Korean (ko)
Inventor
리처드 비. 가이노르
락시미 스리니바산
아사프 포란
듀이 하르잔토
크리스티나 쿠크신
다니엘 아브람 로텐버그
존 스로우지
우구르 사힌
Original Assignee
비온테크 에스이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 비온테크 에스이 filed Critical 비온테크 에스이
Publication of KR20230004508A publication Critical patent/KR20230004508A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
KR1020227036217A 2020-03-20 2021-03-19 코로나바이러스 백신 및 사용 방법 Pending KR20230004508A (ko)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202062992666P 2020-03-20 2020-03-20
US62/992,666 2020-03-20
US202063026559P 2020-05-18 2020-05-18
US63/026,559 2020-05-18
US202063059582P 2020-07-31 2020-07-31
US63/059,582 2020-07-31
US202063086519P 2020-10-01 2020-10-01
US63/086,519 2020-10-01
US202063122904P 2020-12-08 2020-12-08
US63/122,904 2020-12-08
PCT/US2021/023267 WO2021188969A2 (en) 2020-03-20 2021-03-19 Coronavirus vaccines and methods of use

Publications (1)

Publication Number Publication Date
KR20230004508A true KR20230004508A (ko) 2023-01-06

Family

ID=77771752

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227036217A Pending KR20230004508A (ko) 2020-03-20 2021-03-19 코로나바이러스 백신 및 사용 방법

Country Status (11)

Country Link
US (2) US20230141371A1 (https=)
EP (1) EP4121104A4 (https=)
JP (1) JP2023518821A (https=)
KR (1) KR20230004508A (https=)
AU (1) AU2021237720A1 (https=)
BR (1) BR112022018819A2 (https=)
CA (1) CA3172315A1 (https=)
IL (1) IL296617A (https=)
MX (1) MX2022011671A (https=)
TW (1) TW202200199A (https=)
WO (1) WO2021188969A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025164815A1 (ko) * 2024-01-29 2025-08-07 주식회사 나이벡 안지오텐신전환효소 2(ace2)에 대한 결합능이 있는 신규한 펩타이드 및 이의 용도

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4103231A4 (en) 2020-02-14 2024-03-27 Geovax, Inc. VACCINES AND THEIR USES TO INDUCE AN IMMUNE RESPONSE AGAINST SARS-COV2
US20230184764A1 (en) * 2020-04-06 2023-06-15 The Trustees Of Columbia University In The City Of New York Peptide sequences for detection and differentiation of antibody responses to sars-cov-2 and other human corona viruses
US12558415B2 (en) * 2020-04-14 2026-02-24 The Regents Of The University Of California Broad-spectrum multi-antigen pan-coronavirus vaccine
IL297419B2 (en) 2020-04-22 2025-02-01 BioNTech SE Coronavirus vaccine
US20230241202A1 (en) * 2020-05-29 2023-08-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Adenovirus-Based SARS-CoV-2 Vaccine
US20230263883A1 (en) * 2020-07-08 2023-08-24 The Brigham And Women`S Hospital, Inc. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) Peptide Epitopes
WO2022025264A1 (ja) * 2020-07-31 2022-02-03 東亞合成株式会社 ＳＡＲＳ－ＣｏＶ－２由来のアミノ酸配列およびその利用
US12247978B2 (en) * 2020-08-05 2025-03-11 Arizona Board Of Regents On Behalf Of Northern Arizona University Compositions and methods for detection and treatment of coronavirus infection
TWI884296B (zh) * 2020-08-11 2025-05-21 美商碩騰服務公司 抗冠狀病毒疫苗
CN112029781B (zh) * 2020-08-14 2023-01-03 中山大学 一种新型冠状病毒SARS-CoV-2的安全型复制子系统及其应用
US12419948B2 (en) * 2020-08-31 2025-09-23 The Broad Institute, Inc. Immunogenic compositions and use thereof
WO2022051223A1 (en) * 2020-09-02 2022-03-10 The Feinstein Institutes For Medical Research Use of sars-cov-2 receptor binding motif (rbm)-reactive monoclonal antibodies to treat covid-19
JP2023550094A (ja) * 2020-11-12 2023-11-30 ティースキャン セラピューティクス インコーポレイテッド Ｓａｒｓ－ｃｏｖ－２免疫優性ペプチドの構築物及びその使用
JP7598538B2 (ja) 2021-01-29 2024-12-12 東亞合成株式会社 ＳＡＲＳ－ＣｏＶ－２由来のアミノ酸配列およびその利用
US20240192211A1 (en) * 2021-02-24 2024-06-13 Biotome Pty Ltd Peptides and their use in diagnosis of sars-cov-2 infection
US20220356212A1 (en) * 2021-03-26 2022-11-10 Nanogen Pharmaceutical Biotechnology JSC Modified spike protein and method of treatment
EP4070814A1 (en) * 2021-04-07 2022-10-12 Lama France Sars-cov-2 polypeptides and uses thereof
DK4319803T3 (da) 2021-04-08 2025-12-15 Vaxthera Sas Coronavirusvaccine omfattende et mosaikprotein
WO2022221189A1 (en) * 2021-04-12 2022-10-20 La Jolla Institute For Immunology Coronavirus t cell epitopes and uses thereof
WO2022268916A2 (en) * 2021-06-23 2022-12-29 Ose Immunotherapeutics Pan-coronavirus peptide vaccine
WO2023044542A1 (en) * 2021-09-24 2023-03-30 The University Of Adelaide Sars cov-2 vaccine
WO2023049983A1 (en) * 2021-09-28 2023-04-06 Medicago Inc. Cpmv vlps displaying sars-cov-2 epitopes
CN113981140B (zh) * 2021-10-09 2024-02-27 广州达安基因股份有限公司 新型冠状病毒德尔塔突变株的检测方法及核酸检测试剂盒
EP4419136A1 (en) * 2021-10-21 2024-08-28 BioNTech SE Coronavirus vaccine
WO2023067193A2 (en) 2021-10-22 2023-04-27 BioNTech SE Compositions for administration of different doses of rna
US20250295755A1 (en) 2021-10-22 2025-09-25 Sail Biomedicines, Inc. Mrna vaccine composition
WO2023096896A2 (en) * 2021-11-23 2023-06-01 nference, inc. Detection of covid-19 associated cardiac injury and vaccine-associated myocarditis
CA3238764A1 (en) 2021-11-23 2023-06-01 Siddharth Patel A bacteria-derived lipid composition and use thereof
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
EP4445906A1 (en) * 2021-12-08 2024-10-16 Anda Biology Medicine Development (Shenzhen) Co., Ltd. Antigenic polypeptide and use thereof
EP4452239A1 (en) 2021-12-20 2024-10-30 Sail Biomedicines, Inc. Compositions comprising mrna and lipid reconstructed plant messenger packs
CN114686620B (zh) * 2022-01-21 2024-05-07 生物岛实验室 新型冠状病毒多种变异株核酸质谱检测的引物组合、试剂盒及检测方法
CN114729373B (zh) * 2022-01-27 2023-01-31 深圳市瑞吉生物科技有限公司 一种新型冠状病毒mRNA疫苗及其制备方法与应用
EP4469079A1 (en) * 2022-01-28 2024-12-04 Pfizer Inc. Coronavirus antigen variants
WO2023147091A1 (en) * 2022-01-28 2023-08-03 BioNTech SE Coronavirus vaccine
AU2023219116A1 (en) * 2022-02-08 2024-08-15 Iowa State University Research Foundation, Inc. Mrna expression and delivery systems
GB202201768D0 (en) * 2022-02-11 2022-03-30 Virax Biolabs Uk Ltd Peptides
EP4486375A1 (en) * 2022-03-02 2025-01-08 ISR Immune System Regulation Holding AB (publ) Vaccine composition comprising an antigen and a tlr3 agonist
CN116768988A (zh) * 2022-03-09 2023-09-19 中生复诺健生物科技(上海)有限公司 编码新型冠状病毒S蛋白的mRNA疫苗
CN114907452B (zh) * 2022-04-08 2023-07-25 国科宁波生命与健康产业研究院 一种用于治疗SARS-CoV-2病毒感染的M蛋白多肽
CN114907454A (zh) * 2022-04-08 2022-08-16 国科宁波生命与健康产业研究院 一种用于治疗SARS-CoV-2病毒感染的N蛋白多肽
CN114907453B (zh) * 2022-04-08 2023-07-25 国科宁波生命与健康产业研究院 一种用于治疗SARS-CoV-2病毒感染的S蛋白多肽
WO2023213990A1 (en) 2022-05-05 2023-11-09 Etherna Immunotherapies Nv Multi-epitope construct
WO2024002985A1 (en) 2022-06-26 2024-01-04 BioNTech SE Coronavirus vaccine
LU103079B1 (en) * 2023-02-28 2024-08-28 PMCR GmbH IMMUNIZATION AGAINST VIRAL INFECTIONS DISEASE(S)
EP4631527A1 (en) * 2022-12-09 2025-10-15 Seoul National University R&DB Foundation Nanoparticle comprising peptide-based conjugate for delivering mrna into b cell and t cell and uses thereof
EP4631528A1 (en) * 2022-12-09 2025-10-15 Nibec Co., Ltd. Nanoparticle comprising peptide-based conjugate for delivering oligonucleotide into target cell and pharmaceutical composition comprising same
JP2026501447A (ja) * 2022-12-16 2026-01-15 ジーニアス・バイオテクノロジー・インコーポレイテッド 多重抗原性ｒｎａ ｓａｒｓ－ｃｏｖ－２ワクチン及び関連する方法
PL443854A1 (pl) * 2023-02-22 2024-08-26 Instytut Immunologii I Terapii Doświadczalnej Polskiej Akademii Nauk Epitop pochodzący z białka N wirusa SARS-CoV-2, zawierający go antygen, ich zastosowania i sposób wykrywania choroby wywoływanej przez koronawirusa
EP4669348A1 (en) 2023-02-24 2025-12-31 BioNTech SE IMMUNOGENEOUS COMPOSITIONS
EP4676530A2 (en) * 2023-03-06 2026-01-14 Vakston, Inc. Nucleocapsid antigen immunotherapy for covid-19 fusion proteins and methods of use
WO2024263826A1 (en) * 2023-06-22 2024-12-26 Modernatx, Inc. Sars-cov-2 t cell vaccines
WO2025101631A2 (en) * 2023-11-07 2025-05-15 BioNTech SE Compositions and methods for preparing vaccines
WO2025106754A1 (en) 2023-11-15 2025-05-22 BioNTech SE Coronavirus vaccine
FR3155424A1 (fr) 2023-11-15 2025-05-23 BioNTech SE Compositions immunogènes contre le sars-cov-2
CN118955657B (zh) * 2024-01-09 2025-03-04 中山大学 一种特异性表位多肽及其试剂盒和应用
CN119144611A (zh) * 2024-09-19 2024-12-17 宁夏农林科学院枸杞科学研究所 黑果枸杞LrCHS2基因及其编码蛋白在促进枸杞花青素生物合成中的应用
CN120081914A (zh) * 2025-01-03 2025-06-03 中国人民解放军军事科学院军事医学研究院 一种HLA-C限制性SARS-CoV-2淋巴细胞抗原表位肽及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005012337A2 (en) * 2003-07-15 2005-02-10 Crucell Holland B.V. Antigenic peptides of sars coronavirus and uses thereof
US20050106563A1 (en) * 2003-09-08 2005-05-19 Genesis Biotech Inc. Epitope profiles of SARS coronavirus
CN100408595C (zh) * 2003-12-31 2008-08-06 第二军医大学免疫学研究所 Sars病毒hla-a2限制性表位多肽及其应用
CN101085812B (zh) * 2006-06-08 2010-12-01 中国科学院上海生命科学研究院 一种sars冠状病毒多肽抗原及其应用
JP5686370B2 (ja) * 2008-11-28 2015-03-18 日油株式会社 Ｓａｒｓコロナウイルスの細胞傷害性ｔ細胞エピトープペプチド及びその用途
BR112014013745B1 (pt) * 2011-12-09 2022-06-14 Institut Pasteur Método de teste in vitro, kit de detecção e seu uso, método in vitro de diagnóstico, método de fabricação de kit, e teste de imunosseleção multiplex
EP3325646B1 (en) * 2015-07-22 2020-08-19 F.Hoffmann-La Roche Ag Identification of antigen epitopes and immune sequences recognizing the antigens

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025164815A1 (ko) * 2024-01-29 2025-08-07 주식회사 나이벡 안지오텐신전환효소 2(ace2)에 대한 결합능이 있는 신규한 펩타이드 및 이의 용도

Also Published As

Publication number Publication date
WO2021188969A2 (en) 2021-09-23
MX2022011671A (es) 2023-01-24
CA3172315A1 (en) 2021-09-23
EP4121104A4 (en) 2025-12-17
BR112022018819A2 (pt) 2022-11-29
EP4121104A2 (en) 2023-01-25
US20230083931A1 (en) 2023-03-16
JP2023518821A (ja) 2023-05-08
US20230141371A1 (en) 2023-05-11
IL296617A (en) 2022-11-01
AU2021237720A1 (en) 2022-11-17
WO2021188969A3 (en) 2021-11-25
TW202200199A (zh) 2022-01-01

Similar Documents

Publication Publication Date Title
KR20230004508A (ko) 코로나바이러스 백신 및 사용 방법
JP7754971B2 (ja) ネオ抗原およびそれらの使用
RU2682726C9 (ru) Вакцинная композиция против злокачественной опухоли
US12303561B2 (en) Protein antigens and uses thereof
JP2004512814A (ja) ペプチドおよび核酸組成物を使用する、ヒトパピローマウイルスに対する細胞性免疫応答の誘導
JP2003510099A (ja) ペプチドおよび核酸組成物を使用する、ヒト免疫不全ウイルス−１に対する細胞性免疫応答の誘導
JP2017518051A (ja) Ｂ型肝炎ウイルス感染に対する治療ワクチン接種のための合成長鎖ペプチド（ｓｌｐ）
WO2007049737A1 (ja) エプスタイン-バールウイルス感染細胞を特異的に攻撃する細胞傷害性t細胞エピトープペプチド及びその用途
WO2023049272A1 (en) Coronavirus vaccines and methods of use
US12534497B2 (en) TEIPP peptide variant and use as a medicament
WO2007015540A1 (ja) 細胞傷害性ｔ細胞エピトープペプチド及びその用途
JP2025510320A (ja) エピトープの組合せ及びその使用、ワクチン構築物、免疫応答を誘導する方法、エピトープを特定する方法
WO2005068632A1 (ja) ＨＬＡ−Ａ２４０２拘束性Ｅｐ−ＣＡＭ特異的ＣＴＬが認識するエピトープ・ペプチド及びその用途
CN116710126A (zh) 冠状病毒疫苗和使用方法
AU2023283812A1 (en) Viral peptides and uses thereof
NL2034658B1 (en) TIMP3-derived TEIPP neoantigens and uses thereof
NL2034657B1 (en) RCN1-derived TEIPP neoantigens and uses thereof
WO2022244891A1 (ja) ＳＡＲＳ－ＣｏＶ－２由来のＴ細胞エピトープペプチド

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

D13 Search requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D13-SRH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000